image
Healthcare - Medical - Devices - NYSE - GB
$ 24.89
1.01 %
$ 10.9 B
Market Cap
35.56
P/E
1. INTRINSIC VALUE

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems.[ Read More ]

The intrinsic value of one SNN stock under the base case scenario is HIDDEN Compared to the current market price of 24.9 USD, Smith & Nephew plc is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart SNN

image
FINANCIALS
5.55 B REVENUE
6.40%
425 M OPERATING INCOME
-36.09%
263 M NET INCOME
17.94%
608 M OPERATING CASH FLOW
29.91%
-448 M INVESTING CASH FLOW
5.08%
-200 M FINANCING CASH FLOW
78.40%
2.83 B REVENUE
1.23%
328 M OPERATING INCOME
-26.20%
214 M NET INCOME
137.05%
238 M OPERATING CASH FLOW
-51.45%
-360 M INVESTING CASH FLOW
-37.17%
372 M FINANCING CASH FLOW
430.93%
Balance Sheet Decomposition Smith & Nephew plc
image
Current Assets 4.03 B
Cash & Short-Term Investments 302 M
Receivables 1.06 B
Other Current Assets 2.67 B
Non-Current Assets 5.96 B
Long-Term Investments 24 M
PP&E 1.47 B
Other Non-Current Assets 4.46 B
Current Liabilities 2.27 B
Accounts Payable 1.02 B
Short-Term Debt 765 M
Other Current Liabilities 490 M
Non-Current Liabilities 2.5 B
Long-Term Debt 2.32 B
Other Non-Current Liabilities 180 M
EFFICIENCY
Earnings Waterfall Smith & Nephew plc
image
Revenue 5.55 B
Cost Of Revenue 1.85 B
Gross Profit 3.7 B
Operating Expenses 2.76 B
Operating Income 425 M
Other Expenses 162 M
Net Income 263 M
RATIOS
66.70% GROSS MARGIN
66.70%
7.66% OPERATING MARGIN
7.66%
4.74% NET MARGIN
4.74%
5.04% ROE
5.04%
2.63% ROA
2.63%
4.76% ROIC
4.76%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Smith & Nephew plc
image
Net Income 263 M
Depreciation & Amortization 527 M
Capital Expenditures -427 M
Stock-Based Compensation 39 M
Change in Working Capital -332 M
Others 1.54 B
Free Cash Flow 181 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Smith & Nephew plc
image
Wall Street analysts predict an average 1-year price target for SNN of $27 , with forecasts ranging from a low of $27 to a high of $27 .
SNN Lowest Price Target Wall Street Target
27 USD 8.48%
SNN Average Price Target Wall Street Target
27 USD 8.48%
SNN Highest Price Target Wall Street Target
27 USD 8.48%
4. DIVIDEND ANALYSIS
0.94% DIVIDEND YIELD
0.288 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Smith & Nephew plc
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
7. News
Big investors call for break-up of Smith & Nephew, FT reports Three major investors are pushing medical device maker Smith & Nephew to consider a break-up of the business, the Financial Times reported on Thursday, citing shareholders. reuters.com - 3 days ago
Smith & Nephew: Ready To Reap Demographic, Turnaround Dividends Smith & Nephew's Q3 results led to a 13% share price drop due to reduced FY24 guidance, mainly from lower demand in China. Despite short-term challenges, long-term fundamentals remain strong, presenting a buying opportunity at current lower prices. The company's 12-point plan aims to boost growth and margins, focusing on orthopedics, productivity, and accelerating growth in advanced wound management and sports medicine. seekingalpha.com - 6 days ago
Smith & Nephew plc (SNN) Q3 2024 Earnings Conference Call Transcript Smith & Nephew plc (NYSE:SNN ) Q3 2024 Earnings Conference Call October 31, 2024 4:30 AM ET Company Participants Deepak Nath - CEO & Director John Rogers - CFO & Executive Director Conference Call Participants Jack Reynolds-Clark - RBC Capital Management David Adlington - J.P. Morgan Hassan Al-Wakeel - Barclays Robert Davies - Morgan Stanley Richard Felton - Goldman Sachs Graham Doyle - UBS Lisa Clive - Bernstein Julien Dormois - Jefferies Deepak Nath Good morning, and welcome to the Smith & Nephew third quarter trading update. seekingalpha.com - 2 weeks ago
Smith+Nephew slashes revenue outlook as China headwinds emerge British medical equipment manufacturer Smith & Nephew PLC (LSE:SN) slashed its full-year revenue outlook to account for a downturn in demand and pricing pressures in the Chinese market. The FTSE 100-listed group now expects full-year revenue growth of 4.5%, compared to 5-6% growth previously expected. proactiveinvestors.co.uk - 2 weeks ago
Smith & Nephew slashes annual revenue forecast on weak China British medical equipment maker Smith & Nephew cut its annual underlying revenue growth forecast on Thursday to 4.5% from the previous outlook range of 5% to 6%, primarily hurt by challenges in its surgical businesses in China. reuters.com - 2 weeks ago
RENASYS™ EDGE Negative Pressure Wound Therapy System wins Red Dot Award for Design Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, is proud to announce that its RENASYS EDGE Negative Pressure Wound Therapy (NPWT) System has won the Red Dot Award for Design Concept 2024 in the Medical Devices and Technology Category , recognizing its intuitive pairing of NPWT housed in a patient-friendly design. globenewswire.com - 1 month ago
SNN Stock May Gain Following the Co-Marketing Deal With JointVue Smith & Nephew and JointVue announce a co-marketing agreement for the latter's OrthoSonic 3D Surgery Planning Technology. zacks.com - 1 month ago
SNN Boosts Knee Revision Surgery With Its LEGION Hinged Knee System Smith & Nephew introduces the LEGION Hinged Knee System with OXINIUM Technology, elevating knee revision surgery through innovation. zacks.com - 1 month ago
Smith+Nephew partners with JointVue™ for Ultrasound preoperative planning in robotics-assisted surgery Patented technology further personalizes total knee arthroplasty for surgeons and patients Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has signed a co-marketing agreement with JointVue for its patented OrthoSonic™ 3D Surgery Planning Technology – the only ultrasound device currently on the market to deliver 3D preoperative planning. JointVue's technology allows surgeons using Smith+Nephew's CORI◊ Surgical System for robotic-assisted knee arthroplasty to create a personalized surgical plan, which may provide opportunities to improve patient satisfaction and operating room efficiency. globenewswire.com - 1 month ago
SNN Stock Rises on the Completion of First Case With CATALYSTEM System Smith & Nephew announces the completion of the first case using the CATALYSTEM Primary Hip System. zacks.com - 1 month ago
This stock is 'boring' but has 'fantastic' risk-reward: Scharf Eric Lynch from Scharf Investments explains why he likes the non-tech and utilities sectors. youtube.com - 1 month ago
First cases using Smith+Nephew's new CATALYSTEM™ Primary Hip System completed; surgeons hail precision, efficiency and reproducibility Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces promising surgeon feedback from the first completed cases utilizing its new CATALYSTEM Primary Hip System. Designed to address the evolving demands of primary hip surgery - including the increased adoption of anterior approach procedures – the CATALYSTEM Primary Hip System features a triple-taper stem design with uniform proximal loading.1  The reduced distal stem geometry and shorter lengths are ideal for anterior approach but suitable for all approaches.2 globenewswire.com - 1 month ago
8. Profile Summary

Smith & Nephew plc SNN

image
COUNTRY GB
INDUSTRY Medical - Devices
MARKET CAP $ 10.9 B
Dividend Yield 0.94%
Description Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Contact Building 5, Watford, WD18 8YE https://www.smith-nephew.com
IPO Date Nov. 16, 1999
Employees 18000
Officers Ms. Alison Parkes Chief Compliance Officer & Compliance APAC Mr. Paul Connolly President of Global Operations Mr. John Terence Rogers Chief Financial Officer & Executive Director Ms. Helen Barraclough Group General Counsel & Company Secretary Mr. Joe Metzger Senior Vice President of Marketing Services & Communications Mr. Philip G. Cowdy Chief Corporate Development & Corporate Affairs Officer Ms. Elga Lohler Chief Human Resources Officer Dr. Vasant Padmanabhan Ph.D. President of Research & Development and Ear, Nose & Throat Dr. Deepak S. Nath Ph.D. Chief Executive Officer & Director Mr. Andrew Swift Vice President of Investor Relations